A 32-year-old woman presents with nephrotic syndrome (proteinuria 8 g/day, serum albumin 2.1 g/dL, edema). Serology shows negative ANA, negative ANCA, normal complement levels, and normal renal function (creatinine 0.9 mg/dL). Ultrasound shows normal kidney size and echogenicity. What is the most appropriate next step in management?

Explanation

## Clinical Context This 32-year-old woman presents with **nephrotic syndrome** (proteinuria 8 g/day, serum albumin 2.1 g/dL, edema) with: - Negative ANA, negative ANCA, normal complement levels - Normal renal function (creatinine 0.9 mg/dL) - Normal kidney size and echogenicity on ultrasound While the clinical picture may suggest minimal change disease (MCD), the **standard of care in adults with nephrotic syndrome is kidney biopsy before initiating immunosuppressive therapy**. ## Why Kidney Biopsy is the Correct Next Step **Key Point:** Unlike in children (where MCD is so prevalent that empirical steroid therapy is standard), adults with nephrotic syndrome have a broad differential diagnosis — including FSGS, membranous nephropathy, MCD, MPGN, and secondary causes — that cannot be reliably distinguished on clinical grounds alone. **High-Yield:** According to KDIGO guidelines and Harrison's Principles of Internal Medicine (21e, Ch. 279), kidney biopsy is recommended in adults with nephrotic syndrome to establish a definitive histological diagnosis before treatment, because: 1. **FSGS** (focal segmental glomerulosclerosis) — requires different treatment protocols and has a worse prognosis than MCD 2. **Membranous nephropathy** — first-line therapy differs (cyclophosphamide/rituximab-based regimens) 3. **MCD in adults** — steroid response rates are lower (~75–80%) than in children (>90%), and biopsy guides therapy 4. Empirical steroids without biopsy risk inappropriate treatment and delay diagnosis of steroid-resistant pathologies **Clinical Pearl:** The negative serology reduces the likelihood of lupus nephritis and vasculitis, but does NOT narrow the primary glomerular disease differential sufficiently to justify empirical immunosuppression. Normal complement makes MPGN and lupus nephritis less likely, but FSGS and membranous nephropathy remain important considerations. ## Why Option A is Incorrect Empirical prednisolone without biopsy is the **pediatric** approach (children aged 1–8 years with typical nephrotic syndrome). In adults, this approach is not standard because: - The pre-test probability of MCD in adults is lower (~10–15% of adult nephrotic syndrome vs. ~80% in children) - Treating FSGS or membranous nephropathy with steroids alone is suboptimal - Biopsy findings directly guide choice of immunosuppressive agent and predict prognosis ## Management Algorithm ``` Adult Nephrotic Syndrome ↓ Exclude secondary causes (ANA, ANCA, complement, hepatitis, HIV) ↓ Kidney Biopsy (definitive diagnosis) ↓ MCD → Prednisolone 1 mg/kg/day FSGS → Prednisolone ± calcineurin inhibitor Membranous → Cyclophosphamide/rituximab-based regimen ``` **Key Point:** Biopsy is the most appropriate next step in an adult with nephrotic syndrome and negative secondary workup. Empirical therapy without histological diagnosis is not recommended by KDIGO or Harrison's guidelines for adult nephrotic syndrome. [cite: Harrison 21e Ch. 279; KDIGO 2021 Glomerular Disease Guidelines]